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A randomised phase III trial of MVAC (methotrexate, vincristine, doxorubicin, cisplatin) vs gemcitabine and cisplatin (GC) (G
1000 mg m2 days 1, 8, and 15 plus C 70 mg m2 day 2, q 4 wks) indicated GC had similar efficacy and lower toxicity (JCO 2000).
Significant haematologic toxicities in the GC arm occurred on day 15, necessitating dose adjustments in 37% of cycles. We conducted
a phase I/II dose escalation trial using GC on a 21-day cycle, with G and C split between days 1 and 8. The objective of the study to
define maximum-tolerated dose and dose-limiting toxicity (DLT), objective response rate, and overall survival. In all, 32 patients with
locally advanced, relapsed, or metastatic disease received: dose level 1, G/C 1000/35; level 2, 1100/35; level 3, 1200/35; level 4, 1200/
45 mg m2 (G and C given on days 1 and 8 every 3 wks). A total of 19 patients had glomerular filtration rate o60 ml min1 and 19
patients had metastatic disease. Dose-limiting toxicity was haematologic (grade 4 thrombocytopenia) at dose level 2. Of 151 cycles,
at day 15, platelets were o100 in 61 cycles; neutrophils o0.5, platelets o50 in 26 cycles. Only seven cycles were deferred due to
haematological toxicity; four for renal toxicity (chemotherapy instituted posthydration). Overall response rate was 65.5% on an
intention-to-treat analysis (75% [21/28] for assessable patients), with four complete responses (12.5%) and 17 partial responses
(53%). After the median follow-up of 17.2 months (range 13.1–32.4 months), 12 patients remain alive. The overall median survival
was 16 months (range 10.1–26.6 months). G plus C every 3 weeks is active and well tolerated in an outpatient setting, even in
patients receiving prior platinum-based regimens and with poor renal reserve.
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Phase I and II trials in the 1980s demonstrated that metastatic
urothelial transitional cell cancers are chemosensitive. Currently,
systemic combination chemotherapy is the only treatment that
may result in long-term survival for some patients with advanced
or metastatic disease. Although antitumour activity has been
demonstrated with several agents, the median survival associated
with single-agent therapy is 4 –6 months. The median survival time
for combination regimens (e.g. methotrexateþ vinblastine, or
doxorubicinþ cisplatin) is approximately 8 months (Sternberg
et al, 1989). It is known that pretreatment prognostic features have
an impact on individual patient outcome, thus the variation in
reported survival in patients treated with chemotherapy may be
biased by these features (Bajorin et al, 1999; Calabro and
Sternberg, 2002).
In 1985, the Memorial Sloan-Kettering cancer centre (MSKCC)
investigated the four-drug regimen using MVAC (methotrexate,
vincristine, doxorubicin, cisplatin) (Sternberg et al, 1985) in
patients with TCC. They reported an overall response rate of 71%.
These results were later confirmed in a series of 133 patients
(Sternberg et al, 1989). Other studies using the MVAC regimen
reported encouraging response rates including complete responses
of 13–19% (Tannock et al, 1989; Igawa et al, 1990; Boutan-Laroze
et al, 1991). Another study reported the use of MVAC in 21
patients with high-stage TCC. This study, with long-term follow-
up, suggested that the durability of response was disappointing
(Connor et al, 1989). Long-term follow-up evaluation of the
intergroup trial confirmed that MVAC was superior to single-agent
cisplatin in patients with advanced urothelial carcinoma. However,
durable progression-free survival was rare (Saxman et al, 1997).
The combination of CMV (cisplatin, methotrexate, vincristine)
has also been investigated with similar response rates to those
reported with MVAC. A study of 58 patients with metastatic TCC
reported complete responses (CR) in 14 of 50 evaluable patients
and partial responses (PR) in 14 patients for an overall response
rate of 56%. The median survival for CRs was 11 vs 7 months for
PRs (Po0.05) and 6 months for nonresponders. Renal and
haematological toxicities with this regimen were moderate (Harker
et al, 1985).
Although response rates achieved using MVAC have been
encouraging, this regimen has significant toxicity, particularly in
older patients. This is relevant to bladder cancer since the median
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age of patients is approximately 68 years. Many of these patients
have impaired renal function, which may compromise the safety of
the use of cisplatin and increase the risk of toxicity. Indeed, a
significant proportion of otherwise fit patients (around 50% in our
institution) have a calculated glomerular filtration rate
o60 mls min1, the usual cutoff for combination studies with
cisplatin. Treatment with MVAC can result in clinically significant
myelosuppression (up to 25% incidence of neutropenic fever and a
3% drug-related mortality) and significant mucositis (up to 50%
incidence of grade 2– 3 mucositis) (Sternberg et al, 1985, 1989;
Connor et al, 1989; Tannock et al, 1989; Igawa et al, 1990;
Logothetis et al, 1990; Boutan-Laroze et al, 1991; Loehrer et al,
1992). Recent efforts to improve the outcome for patients with
metastatic transitional cell carcinoma have focused on the
identification of new drugs with single-agent activity and on their
incorporation into platinum-based combination regimens. Pacli-
taxel, docetaxel, ifosfamide, and gemcitabine are among the most
active new agents (Hussain and James, 2003).
A large phase III trial randomised 405 patients with stage IV
TCC and with no prior chemotherapy exposure between GC
(gemcitabine 1000 mg m2 days 1, 8, and 15; cisplatin 70 mg m2
day 2) or MVAC every 28 days for a maximum of six cycles.
Overall survival, time to disease progression, time to treatment
failure, and response rate (GC, 49%; MVAC, 46%) were similar in
each arm. Owing to a higher incidence of neutropenic fever and
mucositis, more hospital admissions were required for patients
receiving MVAC (49 admissions for a total of 272 days) compared
to the GC group (9 admissions for a total of 33 days), resulting in
considerably greater hospital resource utilisation (Von Der Maase
et al, 2000). Thus, although this trial was not designed to show
equivalence of the two regimens, many have interpreted the results
as showing therapeutic noninferiority and adopted the GC regimen
as the new standard on the basis of better tolerability (De Wit et al,
2001).
STUDY RATIONALE
Gemcitabine has shown activity in patients with bladder cancer
both as a single-agent and in cisplatin-based combination
regimens. Toxicities with this combination have been mild to
moderate. The dose-limiting side effects have been mainly
haematological, although grade 3 or 4 neutropenic fever is
relatively infrequent. A large phase III trial comparing MVAC
with GC showed that with the same efficacy, GC had a better
toxicity profile (Von Der Maase et al, 2000). Most haematological
toxicity of GC was encountered on day 15, necessitating dose
modifications in 37% of cycles.
Based on these observations, we have investigated the use of GC
utilising a 21-day schedule, omitting day 15 with the aim of
reducing myelotoxicity, thus reducing treatment delays/dose
modifications and increasing dose intensity. It was further
hypothesised that splitting the cisplatin dose over days 1 and 8
may also reduce nephrotoxicity, extending the potential spectrum
of patients eligible for treatment. This combination can be given in
an outpatient setting, thus reducing hospital bed use and
improving cost-effectiveness.
The study protocol was approved by the Local Research Ethics
Committee.
Study objectives
This was a combined phase I/II study of gemcitabineþ cisplatin
given on days 1 and 8 of a 21-day cycle in patients with locally
advanced or metastatic transitional cell carcinoma of the bladder:
(a) Primary objectives: To establish the maximum-tolerated dose
and dose-limiting toxicities.
(b) Secondary Objectives: To estimate the objective response rate
using WHO criteria for response assessment. To estimate
overall survival.
Study treatments
Patients received up to a maximum of six cycles of treatment. All
patients had blood count and clinical chemistry evaluation before
each cycle of chemotherapy. Gemcitabine was given in 500 ml of
0.9% saline and infused over 30 min. This was followed by cisplatin
given with adequate hydration using 0.9% saline pre- and post-
treatment. All drugs were administered via a peripheral intrave-
nous (i.v.) infusion line. Additional hydration, frusemide (i.v. or
oral), potassium, and magnesium supplements were administered
as necessary. Antiemetic therapy comprised 8 mg i.v. dexametha-
sone and 3 mg i.v. granisetron. The total duration of treatment was
approximately 4 h and was carried out in the outpatient clinic.
Study design
The aim of the phase I portion of this study was to define the MTD
of this treatment schedule. A mixed escalation regimen was used as
summarised in Table 1.
Dose-limiting toxicity (DLT) was defined using NCI CTC criteria
as follows: haematological toxicity, grade 4. Nonhaematological
toxicity (except nausea/vomiting and alopecia), grade X3. Starting
at dose level 1, a minimum of three patients were to be recruited
into each dose level. Once they had all completed one cycle of
treatment, if no DLT was observed, subsequent patients were
recruited to the next dose level. If one patient experienced DLT, the
cohort was expanded to a total of six patients. If two or more
patients experienced DLT, then this defined MTD at this dose level,
otherwise dose escalation continued. Patients who were removed
from the study for any reason other than toxicity and failed to
complete the first cycle of treatment were to be replaced. The
planned phase II dose was the dose level immediately below the
MTD.
Planned dose reductions for haematological toxicity
The myelosuppression seen with gemcitabine plus cisplatin (GC)
tends to be short-lived and noncumulative, and so no account of
nadir values was taken for subsequent cycles. All doses were
administered according to the neutrophil and platelet counts in the
24-h period prior to treatment as summarised in Table 2.
Table 2 Dose modifications for haematological toxicity
ANC ( 109 l1),
platelets ( 109 l1) Gemcitabine Cisplatin
41.5 and 4100 100% 100%
0.5–1.5 or 50–100 75% 75%
o0.5 or o50 Delaya/omitb Delaya/omitb
aDay 1 treatments delayed until haematologic status allows treatment. If delay is 43
weeks, the patient will be withdrawn from the study. bDay 8 treatment is omitted.
ANC¼ absolute neutrophil count.
Table 1 Planned dose escalation
Dose level
Gemcitabine
(mg m2)
Cisplatin
(mg m2)
1 1000 35
2 1100 35
3 1200 35
4 1200 45
Systemic chemotherapy for cancer in an outpatient setting
SA Hussain et al
845
British Journal of Cancer (2004) 91(5), 844 – 849& 2004 Cancer Research UK
C
li
n
ic
a
l
PATIENTS AND METHODS
Patients with histologically confirmed muscle invasive primary
transitional cell carcinoma of the bladder and with locally relapsed,
locally advanced or metastatic disease were eligible for the study.
No more than one prior systemic chemotherapy regimen for
primary radical treatment at the time of disease presentation was
permissible. Patients previously treated with radiotherapy were
eligible 3 months post-treatment and after having recovered from
any radiation-related toxicity.
The presence of one or more clinically or radiologically
bidimensionally measurable lesion with one diameter of at least
2 cm was required.
Other criteria for patient entry into this trial were: age greater
than 18 years; life expectancy X12 weeks; WHO performance
status 0–2; adequate haematological function (Hb X10.0 g dl1,
neutrophils X2.0 109 l1, platelets X100 109 l1); adequate
renal function (glomerular filtration rate (GFR) 440 ml min1
calculated using Cockcroft formula); and adequate liver function
(serum bilirubin within normal limits, AST, ALT, ALP o1.5 times
upper limit of normal (ULN), or up to 2.5 times ULN in patients
with liver metastases and ALP allowed to 2.5 times for bone
metastases). Women of child-bearing potential required a negative
pregnancy test prior to entry and both men and women were
required to use an adequate contraceptive method, to be continued
for 3 months after the study.
Patients were given a trial information leaflet and gave written
informed consent before recruitment into the trial.
Response assessment
All patients underwent radiological assessment after completing
three cycles of treatment. Patients responding to the treatment or
showing stable disease continued on treatment to a maximum of
six cycles following which a post-treatment CT scan was
performed. Subsequent CT scans were carried out at 3 monthly
intervals.
Statistical considerations
All patients receiving treatment were included in the toxicity
assessment. Survival analysis was performed on an intention-to-
treat basis. Data were frozen on 1st December 2003. Response and
toxicity data were analysed using simple descriptive statistics.
Survival curves were calculated according to the method of Kaplan
and Meier.
RESULTS
Patient characteristics
A total of 32 patients entered the trial from March 2001 to
December 2002. Patient demographics are summarised in Table 3.
The median age was 66 (range 41– 79) years, 22 male, 10 female. A
total of 19 patients had visceral metastasis and 22 had lymph node
metastasis. Seven patients previously had cystectomy. Eight
patients had previous radiotherapy, of which three had concurrent
chemoradiation. Three had previous platinum-based chemother-
apy. A total of 13 patients had a calculated GFR between 40 and 50
and six between 50 and 60 ml min1.
Detailed analysis was carried out at the time of censor date (1st
December 2003). In total, 23 patients received treatment at dose
level 1 and nine patients at dose level 2. Once the DLT was
achieved, the trial continued to recruit patients in the phase II part
of the study at the dose level immediately below the maximum-
tolerated dose. In all, 151 cycles of gemcitabine and cisplatin
chemotherapy in a 3 weekly schedule were delivered. Toxicity
assessment is based on 151 cycles of chemotherapy delivered to
these 32 patients.
Toxicity
At dose level 1, there was one episode of grade IV gastrointestinal
perforation, which was thought to be unrelated to trial medication
and so the patient was replaced in the cohort. No DLT was
observed at dose level 1 and therefore subsequent patients were
recruited to dose level 2.
At dose level 2, nine patients were treated. Toxicity is
summarised in Table 4. Three patients experienced grade IV
thrombocytopenia, thus defining the DLT. Two of nine patients
also developed grade IV neutropenia.
The phase II portion of the study then proceeded using dose
level 1. In total, 23 patients have been treated at dose level 1, four
in phase I and 19 in phase II. Grade III/IV thrombocytopenia
occurred in 12 of 23 patients, occurring on day 15 but with no
clinical sequelae.
In terms of nonhaematological toxicity, there were three early
deaths. One patient developed gastrointestinal perforation while
taking steroids as an antiemetic. One patient developed gastro-
intestinal bleeding while on warfarin for deep venous thrombosis.
A further patient developed abdominal pain while on chemother-
apy. This prompted laparatomy, at which no intra-abdominal
pathology was evident. However, the patient subsequently died.
No diarrhoea, ototoxicity, nephrotoxicity, or pulmonary toxicity
has been observed. One patient developed grade II peripheral
neuropathy 10 weeks after completing chemotherapy treatment.
Table 3 Patient characteristics
Patient number 32
Tumour grade
II 1
III 31
Stage
T1 2
T2 3
T3A 2
T3B 7
T4 18
N0 9
N1 23
M0 13
M1 19
Table 4 Summary of toxicities
Toxicity
CTC
grade
Dose level 1
(23 patients)
Dose level 2
(nine patients)
Haematological Thrombocytopenia 3 10
4 2 3 (DLT)
Neutropenia 3 9
4 2 (DLT)
Anaemia 3 4
4
Gastrointestinal Perforation 4 1
Haemorrhage 4 1
Other 4 1
Nausea 2 4
3 2
Neurological 2 1
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Response to therapy
Efficacy analysis has been performed on an intention-to-treat
basis. Four patients achieved a CR (four of 32, 12.5%) and 17
patients had a PR (17 of 32, 53%) to treatment. Thus, an overall
response rate of 65.5% (21 of 32) was seen. Six patients had stable
disease and one patient had disease progression. Four of the 32
patients did not undergo radiological response assessment; three
in view of early death, and one patient declined any further
treatment after first week of chemotherapy treatment. Response
rate for patients who underwent radiological reassessment was
75% (21 of 28). Response assessment is summarised in Tables 5
and 6. Examples of radiological responses are shown in Figure 1.
Survival
At the time of censor, 20 of the 32 patients had died. The median
follow-up for the 12 patients remaining alive was 17.2 months
(range 13.1– 32.4 months). Survival data are summarised in
Figure 2. The median survival for all patients was 16.0 months
(10.1–26.6 months) and for the 23 patients treated at dose level 1
was 13.8 months (10.1–yet to be achieved).
Renal function
In only one case chemotherapy was deferred for a week because of
renal toxicity. This patient received the chemotherapy a week later
as renal function improved following hydration. No clinically
significant decline in renal function was noted in any patient
during this study (Figure 3). This is encouraging particularly since
patients with a GFR of 440 ml min1 were included in this study.
This is much less than the cutoff level GFR of 60 ml min1
employed by many of the reported trials using cisplatin-based
combination chemotherapy. Indeed, half of the patients in this
study had a GFR o60 ml min1, which may have excluded them
from other cisplatin-based trials.
Table 5 Response assessment
Response Patient number (%)
CR 4 (12.5%)
PR 17 (53%)
SD 6 (19%)
PD 1 (3%)
NA 4 (12.5%)
CR¼ complete response; PR¼ partial response; SD¼ stable disease; PD¼ progres-
sive disease; NA¼ not assessable.
Table 6 Response assessment by stage
Stage
Patient
number
Objective response:
CR+PR (number (%))
T4 N0 M0 2 1
T1 – 4 N1 M0 11 9 (82%)
T1 – 4 N0 – 1 M1 19 11 (58%)
CR¼ complete response; PR¼ partial response.
A
B
C
D
Figure 1 Radiological response assessment. (A) Pretreatment-enhanced
axial CT scan through mid-abdomen demonstrates enlarged para-aortic
nodes between aorta and left psoas muscle (arrow). Post-treatment scan at
same level (B) demonstrates regression of nodal disease, a tiny focus of
residual density is apparent (arrow). (C) Pretreatment axial CT through
thorax demonstrates a measurable soft tissue nodule in the right middle
lobe on lung window settings (arrow); post-treatment (D) the nodule has
reduced in size, a small ill-defined density is still apparent (arrow).
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Figure 3 Effect of chemotherapy on renal function.
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Dose intensity
This regimen was well tolerated, with most haematological
toxicities occurring on day 15, the planned rest day. Thus, we
were able to deliver chemotherapy drugs as planned in a majority
of cases, the median dose intensity delivered being 92% (range 75–
100%). On day 15, platelets were o100 in 61 of 151 cycle of
chemotherapy, which would have necessitated dose modification
in the standard GC schedule (Von Der Maase et al, 2000).
Furthermore, on day 15, a neutrophil count of o0.5 and/or a
platelet count of o50 was seen in 26 of 151 cycles of treatment,
which would have led to dose omission in the 28-day schedule
(treatment days 1, 8, and 15). These data advocate the case for a
21-day schedule as a means of increasing the delivered dose
intensity of the combination of gemcitabine and cisplatin.
DISCUSSION
The hope from the early 1980s that metastatic bladder cancer
would one day be cured using chemotherapy is yet to be realised. It
is important that new combinations and new schedules are
evaluated in a clinical trial setting to improve the outcome for
patients with this disease. This study using gemcitabine and
cisplatin in a 21-day schedule in an outpatient setting illuminates
many interesting aspects of chemotherapy treatment. This
combination has been used previously but in an in-patient setting
and in trials where patient entry criteria of GFR 460 ml min1
would have excluded half of the patients treated in our trial.
In the series presented here 60% of patients had visceral
metastases, a known poor prognostic indicator. In addition, eight
patients had relapsed after radical radiotherapy, seven had
relapsed after cystectomy and three had disease progression after
previous cisplatin-based chemotherapy. Taking into account these
unfavourable characteristics, a response rate of 65.5% in this group
of patients is encouraging and is comparable with many studies
using standard chemotherapy treatments and reports of other new
treatment schedules. We report a CR rate of 12.5%, which is very
similar to that reported in the published literature. The median
survival of 16 months in this group of patients is, again,
encouraging. These results, along with a favourable toxicity
profile, mandate further investigation of this schedule in large,
prospective randomised studies.
Although not formally assessed in this study, it is likely that
quality of life is enhanced by delivering chemotherapy in an
outpatient setting compared to in-patient treatment. Outpatient
drug delivery also reduces demand for in-patient resources, thus
making it a very attractive and cost-effective mode of chemother-
apy administration.
The dose intensity achieved with this schedule questions the use
of a 28-day schedule and, indeed, further studies of 21-day
schedule are warranted. Optimised treatment with increased dose
delivered and fewer dose delays and dose modifications due to
toxicity may well have an impact on disease free survival and
overall survival. Phase III trials addressing this question are
required. Such trials will also be able to compare directly the
outpatient chemotherapy regimen used in this trial with in-patient
chemotherapy protocols so that quality of life studies can also be
addressed.
In summary, this study, using a fractionated cisplatin regimen
demonstrates that dose delivered can be improved by using day 15
as a rest day from chemotherapy and shortening the cycle length. It
also proves that this regimen can be delivered safely in an
outpatient setting in a group of patients with GFR as low as
40 ml min1. These findings provide a forward step in broadening
the population group who may benefit subjectively and objectively
from the use of palliative chemotherapy. This schedule is already
in use in pilot studies in other regions of UK.
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